Skip to main content

GLPG1690-CL-304 A Phase 3 randomized double blind parallel group, placebo controlled multicenter study to evaluate efficacy and safety of 2 doses of GLPG1690 in addition to local standard of care

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Galapagos NV

Start Date

May 6, 2019

End Date

April 30, 2023
 

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Galapagos NV

Start Date

May 6, 2019

End Date

April 30, 2023